Drug intelligence / Profile preview

Fractagels

Development stage: Preclinical
Lead developer: Zero Gravity
Modality: Hydrogel Systems → Drug Delivery Systems
Administration: Injectable

Overview

Fractagels are a preclinical-stage technology platform developed by Zero Gravity. These syringe-deliverable hydrogels are engineered to undergo in situ assembly upon injection, forming complex, fractal, and multiscale networks. This hierarchical architecture is intended to provide a robust and biomimetic scaffold for minimally invasive therapies, potentially supporting applications in tissue engineering, regenerative medicine, or controlled drug delivery. Currently categorized as a moonshot research direction, the platform focuses on the physical and structural properties of the hydrogel network to enable therapeutic interventions without the need for invasive surgery.

Brand names: Fractagels
Other names: Zero Gravity injectable hydrogel

Beyond the preview

Go deeper on Fractagels.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Fractagels.

Explore the full profile